Financials
Financial year 2025
Worth noting
- More debts than assets in the latest financial year.
- A loss two years in a row.
- The team shrank two years in a row.
- Little cash and receivables against the short-term debts.
- Figures corrected afterwards (2021).
Gross margin
€ -528,262
▼ 338% vs 2024
Profit
Caution€ -4.6 million
▲ 2% vs 2024
Debts
High€ 4.7 million
▼ 59% vs 2024
ReWind Therapeutics from Leuven, company number BE0682626216, closed financial year 2025 with a result of € -4.6 million after tax. For that financial year ReWind Therapeutics recorded a gross margin of € -528,262 and equity of € -2.6 million. Compared with financial year 2024, the result moved from € -4.7 million to € -4.6 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 8, 2026.
What happened at ReWind Therapeutics?
What happened at ReWind Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Participatiemaatschappij Vlaanderen NV stepped down as director. NBB
- Bioskills BV stepped down as director. NBB
- Bauke Anninga stepped down as director. NBB
- Cornelis Been stepped down as director. NBB
- Claus Asbjorn Andersson stepped down as director. NBB
- Stefan Lohmer stepped down as director. NBB
- Stefaan Allemeersch stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 4.6 million. Source: NBB ↗
In short
From € 2.9 million loss in 2021 to € 4.6 million loss in 2025.
On average € 113,100 of value added per employee in 2021.
A new publication or filing at ReWind Therapeutics? We notify you, reason included.
Follow ReWind TherapeuticsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind ReWind Therapeutics is Paul Nicklin.
Directors
According to the 2025 annual accounts
Paul Nicklin
Director
since 2025
Participatiemaatschappij Vlaanderen NV
Director · represented by Tobias Wilms
Also active at: VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK, Arts Gebroeders immobilière, BEDRIJVENCENTRUM VILVOORDE +141 more
since 2024 · until 2030
Chairman of the board · represented by Jim Van Heusden
Also active at: SPICA THERAPEUTICS
since 2024 · until 2030
Claus Asbjorn Andersson
Director
since 2023 · until 2029
Bauke Anninga
Director
since 2024 · until 2030
Stefan Lohmer
Director
since 2022 · until 2027
Stefaan Allemeersch
Director
since 2022 · until 2027
Cornelis Been
Director
since 2024 · until 2030
Establishments
Establishment units
Physical locations of this company
Gaston Geenslaan 3
3001 Leuven
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.
QUOMAK
€ 4.6 million gross margin · 2025
Metaptys
€ 1.3 million gross margin · 2025
Perseus Biomics
€ 320,026 gross margin · 2025
AUGUSTINE THERAPEUTICS same network
€ -1.7 million gross margin · 2025
Montis Biosciences
€ -2.1 million gross margin · 2025
+6 more
Details
- Company number
- 0682.626.216
- VAT number
- BE 0682.626.216
- Registered office
- Gaston Geenslaan 3, 3001 Leuven
- Names & denominations
- ReWind Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 6 October 2017
- Peppol
- Active · Active since 9 Dec 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied